ALD 301

Drug Profile

ALD 301

Alternative Names: ALD-301

Latest Information Update: 31 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aldagen
  • Developer Aldagen; National Heart, Lung and Blood Institute; University of Texas Health Science Center at Houston
  • Class Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Peripheral arterial occlusive disorders

Most Recent Events

  • 31 Aug 2016 ALD 301 is still in phase II trials for Peripheral arterial occlusive disorders in USA (IM)
  • 13 Nov 2014 Cytomedix changes name to Nuo Therapeutics
  • 31 Mar 2014 ALD 301 is available for licensing as of 31 Mar 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top